CALAN SR 240 (Calan SR 240 mg)
Generic Name: verapamil
This pill with imprint "CALAN SR 240" is Green, Elliptical / Oval and has been identified as Calan SR 240 mg. It is supplied by Pfizer U.S. Pharmaceuticals Group.
Calan SR is used in the treatment of migraine prevention; cluster headaches; supraventricular tachycardia; arrhythmia; angina (and more), and belongs to the drug classes calcium channel blocking agents, group IV antiarrhythmics. Risk cannot be ruled out during pregnancy. Calan SR 240 mg is not a controlled substance under the Controlled Substance Act (CSA).
Calan SR
- Generic Name:
- verapamil
- Imprint:
- CALAN SR 240
- Strength:
- 240 mg
- Color:
- Green
- Size:
- 19.00 mm
- Shape:
- Elliptical / Oval
- Availability:
- Prescription only
- Drug Class:
- Calcium channel blocking agents
Group IV antiarrhythmics - Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- Pfizer U.S. Pharmaceuticals Group
- Inactive Ingredients:
- carnauba wax
hypromellose
magnesium stearate
microcrystalline cellulose
polyethylene glycol
magnesium silicate
titanium dioxide
D&C Yellow No. 10
FD&C Blue No. 2
aluminum oxide
Note: Inactive ingredients may vary.
More about Calan SR (verapamil)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 9 Reviews – Add your own review/rating
- Generic Availability
- Drug class: calcium channel blocking agents
Consumer resources
Other brands: Verelan, Isoptin SR, Covera-HS, Verelan PM
Professional resources
Other Formulations
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
